Download Files:
AT-007
$75 – $680
Products Details
Product Description
– AT-007 is an orally active central nervous system (CNS) penetrant Aldose Reductase inhibitor for treatment of Galactosemia with an IC50 value of 100 pM. AT-007 reduces toxic galactitol levels and prevents disease complications in GALT deficiency rats[1][2].
Web ID
– HY-129586
Storage Temperature
– -20°C, 3 years; 4°C, 2 years (Powder)
Shipping
– Room Temperature
Applications
– Neuroscience-Neuromodulation
Molecular Formula
– C17H10F3N3O3S2
References
– [1]Maeve Conneighton, et al. Applied Therapeutics Announces Initiation of Phase 1/2 Study of AT-007 in Galactosemia.|[2]UNITED STATES SECURITIES AND EXCHANGE COMMISSION. APPLIED THERAPEUTICS, INC.
CAS Number
– 2170729-29-8
Molecular Weight
– 425.40
Compound Purity
– 99.37
SMILES
– O=C(O)CC(C1=CSC=C12)=NN(CC3=NC4=CC(C(F)(F)F)=CC=C4S3)C2=O
Clinical Information
– Phase 3
Research Area
– Metabolic Disease
Solubility
– DMSO : 35.71 mg/mL (ultrasonic)
Target
– Aldose Reductase
Pathway
– Metabolic Enzyme/Protease
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
